10-Q: Personalis Reports Q1 2025 Results: Revenue Up 6% Driven by Pharma and VA MVP, Focus Remains on Clinical Expansion

Personalis, Inc. announces a 6% increase in revenue for Q1 2025, driven by growth in pharma tests and services and population sequencing, while highlighting progress in clinical diagnostics and key partnerships.

Summary

• Personalis, Inc. reported a net loss of $15.75 million, or $0.18 per share, for the quarter ended March 31, 2025.
• Revenue increased by 6% to $20.605 million compared to $19.525 million in the same period last year.
• The increase in revenue was driven by a 39% increase in pharma tests and services and a 181% increase in population sequencing revenue.
• These increases were partially offset by a 69% decrease in enterprise sales revenue.
• The company delivered 2,184 molecular tests in Q1 2025, a 52% increase compared to Q4 2024.
• Cash and short-term investments totaled $185.688 million as of March 31, 2025.
• The company raised $17.8 million in net proceeds from selling common stock under its At-The-Market (ATM) program at a weighted-average price of $5.89 per share.
• The company expects to fulfill the task order received in September 2024 from the VA MVP during the first two quarters of 2025.
• The company anticipates fulfilling the task order received in September 2024 during the first two quarters of 2025.
• The company expects continued growth in revenue from pharma tests and services as demand increases for its Next Personal MRD tests.
• The company expects capital expenditures to be approximately $8.0 million in 2025 and between $7 million to $10 million in each of the years 2026 and 2027.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's revenue growth and positive clinical data, the company is still operating at a loss and faces significant risks. The ATM offering suggests a need for capital, but the company seems to be making progress in key areas.

Positives

• Revenue increased by 6% year-over-year, indicating growth in the business.
• Significant growth in pharma tests and services and population sequencing revenue streams.
• Increase in the number of molecular tests delivered, suggesting higher demand for the company's services.
• Successful capital raise through the ATM program, strengthening the company's financial position.
• Positive clinical data and publications supporting the performance of NeXT Personal in detecting cancer recurrence.
• Medicare coverage determination for NeXT Dx, potentially expanding access to the test.

Negatives

• The company continues to operate at a net loss.
• Decline in enterprise sales revenue, indicating a potential risk in that segment.
• Substantial customer concentration with a limited number of customers accounting for a substantial portion of revenue and accounts receivable.
• The company does not expect to have a long-term commercial relationship with Natera beyond 2025.

Risks

• The company may not be able to generate sufficient revenue to achieve or sustain profitability.
• The company has substantial customer concentration, with a limited number of customers accounting for a substantial portion of revenue and accounts receivable.
• The company relies on a limited number of suppliers, or in some cases, a sole supplier, for some laboratory instruments and materials.
• The company has a single facility and if it becomes damaged or inoperable, its ability to sell and provide its services and pursue research and development efforts may be jeopardized.
• The company may not be able to manage its future growth effectively, which could make it difficult to execute its business strategy.
• The company may acquire businesses or assets, form joint ventures, or make investments in other companies or technologies that could harm its operating results, dilute stockholders ownership, or cause it to incur debt or significant expense.
• The company's tests may be subject to regulatory action if regulatory agencies or authorities determine that its tests do not appropriately comply with statutory and regulatory requirements enforced by the FDA, or equivalent foreign regulatory authorities and/or CLIA requirements for quality laboratory testing or equivalent foreign requirements.
• The company's internal information technology systems, or those of its third-party vendors, contractors, or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could adversely affect its business.
• The company's employees may engage in misconduct or other improper activities, such as noncompliance with regulatory standards and requirements, including the Foreign Corrupt Practices Act of 1977 and other anti-bribery laws, which could cause significant liability for the company and harm its reputation.
• The company's inability to raise additional capital on acceptable terms in the future may limit its ability to continue to operate its business and further expand its operations.
• The market price of the company's common stock may be volatile or may decline steeply or suddenly regardless of its operating performance, it may not be able to meet investor or analyst expectations, and you may lose all or part of your investment.
• The company's quarterly results may fluctuate significantly, which could adversely impact its common stocks value.
• Insiders or holders of greater than five percent of the company's outstanding common stock may exercise significant control over its company and will be able to influence corporate matters.
• Future sales of shares by existing stockholders, or the perception that such sales could occur, could cause the stock price of its common stock to decline.
• The company does not currently intend to pay dividends on its common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of its common stock.
• If securities or industry analysts do not publish research or reports about its business, or publish inaccurate or unfavorable research about its business, its stock price and trading volume could decline.
• Delaware law and provisions in its amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer, or proxy contest difficult, thereby depressing the trading price of its common stock; its amended and restated certificate of incorporation has an exclusive forum provision, which could limit its stockholders ability to obtain a favorable judicial forum for disputes with it or its directors, officers, or employees.
• The company's disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

Future Outlook

The company anticipates that its current cash and cash equivalents and short-term investments, together with cash provided by operating activities, are sufficient to fund its near-term capital and operating needs for at least the next 12 months and expects continued growth in revenue from pharma tests and services as demand increases for its Next Personal MRD tests.

Industry Context

The company operates in the competitive field of cancer genomics, facing competition from established players and emerging companies. The company is focused on personalized cancer therapies and MRD detection, aligning with the growing trend of precision medicine. The company's partnerships with pharmaceutical companies and diagnostic providers reflect a collaborative approach to expanding market reach and developing comprehensive solutions.

Comparison to Industry Standards

• Personalis competes with companies like Guardant Health, Foundation Medicine, and Natera in the liquid biopsy and cancer genomics space.
• Guardant Health reported revenue of $167.5 million in Q1 2025, significantly higher than Personalis, but operates with a different business model.
• Natera, while a customer of Personalis, also competes in the MRD testing market with its Signatera assay.
• Foundation Medicine, owned by Roche, offers comprehensive genomic profiling services and has a strong presence in the oncology market.
• Personalis' focus on ultra-sensitive MRD detection and partnerships with pharmaceutical companies differentiates it from some competitors.
• The company's capacity to sequence and analyze over 350 trillion bases of DNA per week positions it as a significant player in the genomics space.

Related Party Transactions

• Includes related party accounts receivable of $ 0.5 million and $ 2.5 million as of March 31, 2025 and December 31, 2024, respectively.
• Includes related party liabilities of $ 2.8 million and $ 1.7 million as of March 31, 2025 and December 31, 2024, respectively.
• Includes related party liabilities of $ 1.2 million and $ 1.2 million as of March 31, 2025 and December 31, 2024, respectively.
• Includes related party revenue of $ 0.5 million for the three months ended March 31, 2025.
• Includes related party sales and marketing expenses of $ 0.6 million for the three months ended March 31, 2025.
• Includes a change in related party receivable of $ 1.9 million for the three months ended March 31, 2025.
• Includes a change in related party liabilities of $ 1.0 million for the three months ended March 31, 2025.

Stakeholder Impact

• Shareholders: Dilution from ATM offering, potential for stock price volatility.
• Employees: Potential for increased workload due to growth, job security dependent on company performance.
• Customers: Access to advanced genomic tests and services, potential for improved cancer treatment outcomes.
• Suppliers: Continued business relationships, potential for increased demand.
• Creditors: Repayment of existing debt, potential for future financing.

Next Steps

• Continue to focus on scaling the business and operations.
• Further develop and commercialize other services and products.
• Execute the sales and marketing strategy for the company's services.
• Generate sufficient reimbursement or coverage by insurance or governmental payors for the company's products.
• Continue to build automation and other infrastructure to scale further as demand increases.
• Continue to selectively invest in areas to enhance the company's services and product offering, in particular NeXT Personal Dx.
• Continue to build and publish the clinical evidence-base to support the company's products and services in its key indications.
• Pursue reimbursement coverage from Medicare and other payors.
• Seek additional partnerships.

Key Dates

Keywords

Personalis, genomics, cancer, revenue, clinical trials, molecular tests, MRD, VA MVP, Moderna, Natera, NeXT Personal Dx, Medicare, ATM program